Loading ...
SUGEN as a cancer derapeutic(passive) designed bya tyrosine - kinase inhibitor drug
SUGEN as a cancer therapeutic(passive) designed bya tyrosine - kinase inhibitor drug
to block the BCR - ABL protein(passive) are designedTyrosine kinase inhibitors
Taiho Pharmaceutical(passive) discovered bytyrosine kinase inhibitor
monoclonal antibodies ( mAbs ) that specifically target mutated EGFR(passive) have been createdTyrosine kinase inhibitors ( TKIs ) and
Merck KGaA , Darmstadt , Germany(passive) discovered bya Bruton ’s Tyrosine Kinase Inhibitor ( BTKi
from 197,116 compounds in the SPECS database here(passive) were discoveredtyrosine kinase inhibitors
ARIAD Pharmaceuticals in the United States(passive) discovered bya tyrosine kinase inhibitor
ARIAD Pharmaceuticals , which was acquired during development by Takeda Pharmaceuticals(passive) was originally discovered byThe tyrosine kinase inhibitor ( TKI
for the bcr - abl fusion protein that is characteristic for Philadelphia chromosome - positive leukemias ( chronic myelogenous leukemia and occasionally acute lymphocytic leukemia(passive) is designed specifically16],[17 ] Imatinib , a tyrosine kinase inhibitor
to inhibit the kinase activity of the TRK A / B / C and ROS1 proteins , whose activating fusions drive proliferation in certain cancer(passive) is designedThe selective tyrosine kinase inhibitor
to block different cytokine receptor signaling pathways(passive) are designedTyrosine kinase inhibitors
to blockade the downstream signaling pathways that promote tumor growth and metastasis when stimulated by angiogenic factors(passive) are designedTyrosine kinase inhibitors ( TKI
TKI ) imatinib(passive) was ... designedThe tyrosine kinase inhibitor
to target BCR - ABL1 which is constitutively activated in chronic myeloid leukemia ( CML(passive) was rationally designedThe tyrosine kinase inhibitor ( TKI ) imatinib
to block the action of a specific enzyme called tyrosine kinase(passive) are designedTyrosine kinase inhibitors
Novartis(passive) designed byA tyrosine kinase inhibitor drug
Kyowa Hakko Kirin and approved for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland(passive) discovered bytyrosine kinase inhibitor ( TKI
to have effects against different types of cancer(passive) have been discoveredTyrosine kinase inhibitors
Kyowa Kirin and approved for the treatment of adult patients with advanced renal cell carcinoma ( RCC ) in the European Union plus Norway and Iceland(passive) discovered bytyrosine kinase inhibitor ( TKI
Kyowa Hakko Kirin and approved for the treatment of adult patients with advanced renal cell carcinoma ( RCC ) in the European Union plus Norway and Iceland(passive) discovered bytyrosine kinase inhibitor ( TKI
Kyowa Hakko Kirin and approved for the treatment of adult patients with advanced renal cell carcinoma ( aRCC ) in the European Union plus Norway and Iceland(passive) discovered bytyrosine kinase inhibitor ( TKI
Kyowa Kirin and approved for the treatment of adult patients with advanced renal cell carcinoma ( RCC ) in the European Union plus Norway , New Zealand and Iceland(passive) discovered bytyrosine kinase inhibitor ( TKI
Kyowa Kirin and approved for the treatment of adult patients with advanced renal cell carcinoma ( RCC ) in the European Union , the United Kingdom , Norway , New Zealand and Iceland(passive) discovered bytyrosine kinase inhibitor ( TKI
Anticancer treatment withcausesthe tyrosine kinase inhibitor sunitinib
e.g. cetuximab , EMD72000 , or ABX - EGF ) , or intracellular tyrosine kinase inhibitors ( TKI ; e.g. gefitinib or erlotinib).13 Erlotinib is a EGFR tyrosine kinase protein inhibitorpreventingautophosphorylation of tyrosine kinase
cetuximab EGFR bevacizumab VEGFpreventingangiogenesis tyrosine kinase inhibitors
pyrido[2,3-d]pyrimidinesdesignedas inhibitors of FGFR3 tyrosine kinase
It was usedto designEGFR Tyrosine Kinase Inhibitors
originally(passive) were ... discoveredTyrosine Kinase inhibitors
to have effective antitumor activities(passive) have been discoveredTyrosine kinase inhibitors
to be effective in cases of chronic myeloid leukemia with the T315I mutation , which renders it resistant to other approved therapies(passive) is designedIclusig , a tyrosine kinase inhibitor
These drugs(passive) were designedTyrosine kinase inhibitors
to optimize VEGF blockage while minimizing off - target toxicities(passive) was designedtyrosine kinase inhibitor ( TKI
The use of AG-490 , an inhibitor of the JAK / STAT pathway , in combination with NF - κB andresulteda kinase inhibitor
rapamycin(passive) prevented bythe p27kip1 cyclindependent kinase inhibitor
Related citations Select itemprevents1736741012.Bruton 's tyrosine kinase
to inhibit the breakpoint cluster region ( BCR)-Abelson ( ABL ) fusion protein that arises in Philadelphia chromosome - positive patients ( ~ 90 % of all patients with CML(passive) was rationally designedImatinib , a tyrosine kinase inhibitor
Hengrui pharma in China(passive) invented bya tyrosine kinase inhibitor of VEGF
III studyledthe VEGF - tyrosine kinase inhibitor ( VEGF - TKI ) sunitinib
lung injury and death after intravenous LPS in mice ... Johns Hopkins Universitypreventslung injury and death after intravenous LPS in mice ... Johns Hopkins University
specifically for the bcr - abl fusion protein that is characteristic for Philadelphia chromosome - positive leukemias ( chronic myelogenous leukemia and occasionally acute lymphocytic leukemiadesignedspecifically for the bcr - abl fusion protein that is characteristic for Philadelphia chromosome - positive leukemias ( chronic myelogenous leukemia and occasionally acute lymphocytic leukemia
lung injury and death after intravenous LPS in mice R. Scott Stephens , Laura Johnston , Laura Servinsky , Bo S. Kim , Mahendra Damarla Physiological Reports Nov 2015preventslung injury and death after intravenous LPS in mice R. Scott Stephens , Laura Johnston , Laura Servinsky , Bo S. Kim , Mahendra Damarla Physiological Reports Nov 2015
lung injury and death after intravenous LPS in mice Robert Stephens , Laura Johnston , Laura Servinsky , Bo Soo Kim ... Mahendra Damarlapreventslung injury and death after intravenous LPS in mice Robert Stephens , Laura Johnston , Laura Servinsky , Bo Soo Kim ... Mahendra Damarla
Retinal Pigment Epithelial Cell EMT and Growth | IOVS |PreventRetinal Pigment Epithelial Cell EMT and Growth | IOVS |
Ang IIpreventedAng II
to inhibition of the division and growth of T - cells and some cancer cells activityleadingto inhibition of the division and growth of T - cells and some cancer cells activity
Structural changes(passive) were prevented byStructural changes
to inhibit VEGF signal transduction by binding directly to the ATP - binding sites of VEGFRs ( 23designedto inhibit VEGF signal transduction by binding directly to the ATP - binding sites of VEGFRs ( 23
therapy Acne - form Rash(passive) Caused bytherapy Acne - form Rash
Leukemia Acne - form Rash(passive) Caused byLeukemia Acne - form Rash
Fingernail Acne - form Rash(passive) Caused byFingernail Acne - form Rash
to inhibit the breakpoint cluster region - v - Abelson murine leukemia viral oncogene homolog 1designedto inhibit the breakpoint cluster region - v - Abelson murine leukemia viral oncogene homolog 1
The Human Epidermal Growth Factor Receptor ( Renehan 'sInfluencesThe Human Epidermal Growth Factor Receptor ( Renehan 's
Lung Cancer Treatment Acne - form Rash(passive) Caused byLung Cancer Treatment Acne - form Rash
Print PDF Acne - form Rash(passive) Caused byPrint PDF Acne - form Rash
Genetic characterization to improve interpretation and clinical management of hepatotoxicity(passive) caused byGenetic characterization to improve interpretation and clinical management of hepatotoxicity
hypothyroidism in a patient on levothyroxinecausinghypothyroidism in a patient on levothyroxine
APD90 prolongation also reduced PI3 K activitycausedAPD90 prolongation also reduced PI3 K activity
Receptor - directed monoclonal antibodies as well as(passive) are designedReceptor - directed monoclonal antibodies as well as
To determine if the EGFR tyrosine kinase inhibitor , erlotinib could cause hypomagnesemia , swelling and cardiac tensioncould causeTo determine if the EGFR tyrosine kinase inhibitor , erlotinib could cause hypomagnesemia , swelling and cardiac tension
to work against tumors that resisted treatments such as imatinib due to T315I mutationsdesignedto work against tumors that resisted treatments such as imatinib due to T315I mutations
some serious side effects like cardiotoxicity , anemia , and thrombocytopeniamay causesome serious side effects like cardiotoxicity , anemia , and thrombocytopenia
1 μmol / L genisteinprevented1 μmol / L genistein
to considerable treatment successhave ledto considerable treatment success
disease progression ... but also shrink tumours before surgery ... show the results of a phase II trialcould ... preventdisease progression ... but also shrink tumours before surgery ... show the results of a phase II trial
gene induction and also increase the sensitivity of cells to UVC killing ( Dévary et al . , 1992preventgene induction and also increase the sensitivity of cells to UVC killing ( Dévary et al . , 1992
epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number- dependent mannerpreventsepidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number- dependent manner
to regression of gastrointestinal stromal tumors not only through direct effects on neoplastic tumor cells but also through modulation of T - cell activationcontributesto regression of gastrointestinal stromal tumors not only through direct effects on neoplastic tumor cells but also through modulation of T - cell activation
hypomagnesemia , inflammation and cardiac stressmay causehypomagnesemia , inflammation and cardiac stress
the ability of SPGF to downmodulate ErbB-1influencethe ability of SPGF to downmodulate ErbB-1
as a targeted therapy for patients with non – small - cell lung cancer with specific mutations in epidermal growth factor receptor ( EGFR ) or human epidermal growth factor receptor 2 ( HER2 ) genesdesignedas a targeted therapy for patients with non – small - cell lung cancer with specific mutations in epidermal growth factor receptor ( EGFR ) or human epidermal growth factor receptor 2 ( HER2 ) genes
votrient advanced renal cell carcinoma kidney cancer soft tissue sarcoma tyrosine kinase inhibitor Acne - form Rash(passive) Caused byvotrient advanced renal cell carcinoma kidney cancer soft tissue sarcoma tyrosine kinase inhibitor Acne - form Rash
GH effects on IGF-1 release [ 46preventedGH effects on IGF-1 release [ 46
DAMP / PAMP induced activation of caspase-1can preventDAMP / PAMP induced activation of caspase-1
resistance by induction of generic transcriptional rescue profilescauseresistance by induction of generic transcriptional rescue profiles
specifically for the bcr - abl fusion protein that is characteristic for Philadelphia chromosome Philadelphia chromosome or Philadelphia translocationdesignedspecifically for the bcr - abl fusion protein that is characteristic for Philadelphia chromosome Philadelphia chromosome or Philadelphia translocation
to a revolution in the treatment of chronic myelogenous leukaemiahave ledto a revolution in the treatment of chronic myelogenous leukaemia
harm to the fetus if the treatment is administered during pregnancycan causeharm to the fetus if the treatment is administered during pregnancy
numerous side effects including metabolic consequences ( Thomas et al . , 2015 ; Verstovsek et al . , 2017acausenumerous side effects including metabolic consequences ( Thomas et al . , 2015 ; Verstovsek et al . , 2017a